



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 11, 2025

David Tapolczay, Ph.D.  
Chief Executive Officer  
Conduit Pharmaceuticals Inc.  
4581 Tamiami Trail North, Suite 200  
Naples, Florida 34103

**Re: Conduit Pharmaceuticals Inc.**  
**Registration Statement on Form S-3**  
**Filed February 5, 2025**  
**File No. 333-284714**

Dear David Tapolczay Ph.D.:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Todd Mason, Esq.